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INTRODUCTION
Nephrin, a podocyte-related protein, is a protein to form a ma-
jor component of slit diaphragm that tightly restricts the pass-
ing of large proteins such as albumin.1 Since the discovery of 
nephrin mutation in congenital nephrotic syndrome of the 
Finnish type,2 the role of nephrin in the pathogenesis of diabet-
ic glomerulopathy and proteinuria has been suggested by sev-
eral data.3-10
Preeclampsia (PE) is characterized by proteinuria associated 
with renal pathology delineated as endothelial cell swelling, 
loss of endothelia fenestration, widening of subendothelial 
space, and deposition of hyaline material.11,12 Although the dis-
ruption of basement membrane and podocyte was not evident 
in electron microscopic examination of kidney of preeclamptic 
patient,13 urinary excretion of podocyte and nephrin suggesting 
podocytopathy has been recently observed in patients with 
PE.14-18 Furthermore, in vitro demonstration of nephrin shed-
ding from the podocyte, induced by endothelin-1 secreted 
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from the endothelial cells which were exposed to the sera of PE 
patients, may be the underlying mechanism of proteinuria in 
PE.19 Thus, detecting urinary excretion of podocyte-related pro-
tein may serve as a potent predictive or early diagnostic tool for 
PE. In light of this, a prospective longitudinal study was con-
ducted to evaluate the nephrin levels in serum and urine of 
normal pregnancy to establish a standard reference value and 
to compare them with patients who subsequently developed 
PE.
MATERIALS AND METHODS
Participants
From October 2010 to August 2012, 117 healthy women with 
singleton pregnancies with confirmed gestational age with 
means of ultrasonography in the first trimester were enrolled 
between 6 to 20 weeks of gestation at 2 participating medical 
centers (Yonsei University Healthcare Center and MizMedi 
Women’s Hospital, Seoul, Korea) adhering to a common proto-
col. Women with uncertain dating of the pregnancy, multi-order 
pregnancy, spontaneous abortion, intrauterine fetal death, fetal 
anomaly, diabetes, hypertensive disease, renal disease, gesta-
tional proteinuria, urinary tract infection, vascular or connec-
tive tissue disease, under medication other than multivitamin 
supplement, language barrier, and smoker were considered in-
eligible for the study. Patients complicated with hypertension, 
diabetes, renal disease, or connective tissue disease were also 
excluded from the study. PE was defined as newly onset hyper-
tension (either diastolic blood pressure of at least 90 mm Hg or 
systolic blood pressure of at least 140 mm Hg on two occasions) 
accompanied by clinically significant proteinuria, defined as 
one of the followings: random urine dipstick results of at least 
1+ on two occasions or results of at least 2+; or 24-hour urine 
protein of at least 300 mg. This study was reviewed and ap-
proved by the institutional review board and written informed 
consent was obtained from patients prior to the enrollment.
Procedures
Technicians performing the assays were blinded to the patient’s 
information and pregnancy outcome. Eligible patients were re-
quested to submit urine and serum samples at the time of en-
rollment, at 11 to 15 weeks, 16 to 20 weeks, 21 to 28 weeks, 29 to 
40 weeks of gestation, and at 4 to 6 weeks postpartum. Serum 
and urine samples were stored at -70°C in aliquots until analy-
sis. Enzyme-linked immunosorbent assay (ELISA) for nephrin 
was performed in duplicate with the use of commercial kit 
(USCN Life Science Inc., Wuhan, China). The minimal detect-
able dose was 0.0156 ng/mL for nephrin.
Statistics
Statistical analysis was performed using SAS 9.2 version (SAS 
Institute Inc., Cary, NC, USA). Comparison of basic characteris-
tics between pregnancies with normal outcome and women 
with subsequent PE was conducted using Mann-Whitney U-
test and Fisher’s exact test. Comparison of serum and urine 
nephrin level according to the sampling points was performed 
using Linear mixed model. Comparison of serum and urine 
nephrin levels between normal and patients with subsequent 
PE was conducted using Mann-Whitney U-test. For all analy-
ses, a p-value of <0.05 was considered statistically significant.
RESULTS
Patients’ characteristics 
Of 117 uncomplicated pregnant women enrolled, 9 pregnan-
cies terminated prior to 20 gestational weeks, and 9 delivered 
elsewhere. Among 99 patients (84.6%) who delivered at the 
study centers, 12 patients (12.1%) later developed PE at a medi-
an gestational age of 34+4 weeks (range 29+5–36+6 weeks). At 
postpartum, 16 were loss to follow up following delivery, 2 with-
drew from the study at postpartum, and 1 did not submit urine 
sample. A total of 80 patients were eligible for final analysis. Ba-
sic characteristics of eligible cases and those who developed PE 
are shown in Table 1.
Nephrin levels in serum and urine during gestation 
and at postpartum in normal pregnancies
The mean values of serum and urine nephrin during pregnan-
cy and at postpartum are shown in Table 2. During the latter 
half of pregnancy, a significant decrease in the serum nephrin 
level was observed which corresponded to the increase in the 
level of urine nephrin (Fig. 1).
Subanalysis of 12 patients who subsequently 
developed PE
The median interval between the specimen collection and di-
agnosis of PE was 9 days (range 3–19 days). The nephrin levels 
in specimens obtained prior to the onset of PE from women 
who subsequently developed PE were significantly higher, 
compared to that of the normal pregnant controls (Table 3). In-
crease in serum and urinary nephrin preceded the clinical 
manifestation of PE. However, as delineated in the longitudinal 
plots (Fig. 2), third trimester alteration was more pronounced 
and discriminative in the urine nephrin while the serum level 
overlapped with the normal control.
DISCUSSION
The major findings of this prospective study are: 1) serum 
nephrin level showed a decreasing trend while urine nephrin 
increased in the latter half of the pregnancy, but both values re-
turned to the 1st trimester level at postpartum; and 2) a promi-
nent increase in the serum and urine nephrin level antedated 
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the onset of PE.
Garovic, et al.15 were the first to make an important observa-
tion about a significant excretion of podocyte in the preeclamp-
tic patient’s urine, suggesting podocyturia as a novel marker for 
the diagnosis of PE. Similar to Garovic’s finding, Aita, et al.14 
demonstrated that acute but transient podocyturia in PE is 
closely related to heavy proteinuria. However, when it comes to 
clinical application, determining podocyturia by overnight in-
cubation and staining the urinary cells with podocyte-related 
proteins such as podocin, podocalyxin, neprhin, and synapto-
podin is time-consuming. To better utilize the significant find-
ing of Garovic, et al., subsequent studies pertinent to urinary 
podocyte-specific proteins in PE followed.17,20 In the recent 
studies, soluble podocyte-specific proteins were measured in 
the urine samples, using ELISA rather than cell per se.17,20 The 
result not only demonstrated that the urine concentration of 
nephrin is significantly increased in PE, compared with normal 
pregnancy, but also compared with pregnancy complicated 
with chronic hypertension.20 These data are expected to provide 
a future perspective on the use of urinary podocyte-related pro-
teins, resulting from the podocyte injury and glomerular barrier 
dysfunction occurring in the PE for early diagnosis for PE, or 
differential diagnosis of hypertensive or proteinuric disease 
during pregnancy.
In this context, normative data of serum and urine nephrin 
level during pregnancy should be available to first understand 
the gestational pattern. To our best knowledge, the present 
study is the first to illustrate the gestational changes in serum 
and urine nephrin level in a prospective manner. The reason 
for the decrease and increase of nephrin in serum and urine, 
Table 1. Patients’ Characteristics
Variable Control (n=68) Subsequent PE (n=12) p value*
Gestational age at enrollment (d) 81 (42–171) 67 (47–89) 0.53
Nulliparity, n (%) 35 (51.5) 8 (66.8) 0.33
BMI (cm) 21.2 (16.9–31.2) 21.5 (18.4–31.2) 0.51
SBP at enrollment (mm Hg) 120 (91–134) 120 (100–132) 0.93
DBP at enrollment (mm Hg) 72 (50–88) 64 (50–80) 0.12
Gestational age at diagnosis (d) NA 34+4 (29+5–38+0) -
Gestational age at delivery (d) 39+2 (37+0–41+2) 34+3 (30+0–38+2) <0.001
Birth weight (g) 3310 (2370–4590) 2170 (1920–3060) <0.001
BMI, body mass index; DBP, diastolic blood pressure; PE, preeclampsia; SBP, systolic blood pressure.
Values are n (range) and median (range).
*p-value by Mann-Whitney U-test and Fisher’s exact test.
Table 2. Serum and Urine Nephrin Levels Throughout Pregnancy and at Postpartum
Serum nephrin (ng/mL) p value* Urine nephrin (ng/mL) p value*
<15 wks 99.29±5.29 REF 0.13±0.02 REF
16–20 wks 92.85±5.35 0.08 0.17±0.02 0.11
21–28 wks 78.56±4.68 <0.001 0.24±0.03 <0.05
29–40 wks 68.69±3.63 <0.001 0.26±0.03 <0.001
Postpartum 99.77±5.43 0.62 0.11±0.01 0.39
REF, reference value.
Values expressed as least square mean±SE.
*p-value by Linear mixed model.
Fig. 1. Mean serum (A) and urine (B) nephrin according to gestational weeks. *Represent values that are significantly different from the reference value 
<15 weeks of gestation.
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respectively, during latter half of pregnancy is unclear. Never-
theless, we speculate that the physiologic expansion of plasma 
volume occurring in the latter half of pregnancy may contribute 
to the decrease of serum nephrin level. And as vascular endo-
thelial growth factor (VEGF) blockade is known to induce podo-
cyte injury,19 late increase in the soluble fms-like tyrosine kinase 
1 (sFlt-1) that normally occurs in pregnancy21 may lead to sub-
clinical podocyte injury resulting in increased urinary shedding 
of nephrin. Furthermore, slight podocyturia in the absence of 
clinically significant proteinuria observed in a normal pregnan-
cy substantiates our speculation.14
One concern raised in the present study is that the urine 
nephrin concentration of normal pregnant women at 3rd tri-
mester was much lower than that measured previously by Wang, 
et al.20 (0.26 ng/mL vs. 86 ng/mL). However, this may possibly 
due to difference in commercial immunoassay kit used (USCN 
Life Science vs. Exocell) or difference in subject ethnicity (Kore-
an vs. African).3
Of note, women in whom PE later developed had significant-
ly higher levels of urine nephrin at 32–35 gestational weeks when 
compared to those with normal pregnancy outcome, whereas 
this difference was not evident in the serum nephrin level. This 
observation, albeit small sample size, indicates that the nephrin 
in the urine is not a result of increased filtration of serum neph-
rin, but rather caused by a direct shedding from the renal podo-
cytes injured by circulating factors.
Moreover, the increase in urine nephrin level preceded the 
onset of clinical manifestation of PE by 9 days (range 3–19 d). 
Although the statistical significance cannot be determined due 
to small sample number, the sensitivity and specificity of urine 
nephrin at 3rd trimester at a cutoff value of 0.85 ng/mL were 
100% and 97%, respectively. In comparison, the time interval 
was much greater in serum sFlt-1 and soluble endoglin (sEng) 
with 5 weeks and 2 to 3 months, respectively.21,22 Considering 
the fact that preventive strategy for PE is unavailable at this 
time, use of sFlt-1 and sEng for predicting PE would only make 
Table 3. Comparison of Levels of Serum and Urine Nephrin between Normal and Subsequent PE Patients 
Control (n=68) PE (n=12) p value*
Serum nephrin (ng/mL)
<15 wks 82.91 (39.90–189.50) 80.48 (55.71–108.99) 0.80
16–20 wks 84.08 (27.79–225.60) 88.35 (69.25–200.30) 0.20
21–28 wks 73.15 (21.57–226.92) 145.64 (58.68–210.42) <0.001
29–40 wks 70.00 (18.07–142.66) 100.60 (73.30–131.41) <0.001
Urine nephrin (ng/mL)
<15 wks 0.08 (0.01–1.03) 0.10 (0.01–0.30) 0.49
16–20 wks 0.11 (0.01–0.85) 0.26 (0.10–0.53) 0.33
21–28 wks 0.17 (0.01–1.03) 0.23 (0.09–0.99) 0.78
29–40 wks 0.19 (0.01–1.17) 2.11 (0.85–2.86) <0.001
PE, preeclampsia.
Values are expressed as median (range).
*p-value by Mann-Whitney U test. 
Fig. 2. Longitudinal plots of nephrin levels in serum (A) and urine (B) according to gestational weeks before the onset of PE. Solid lines for normal pregnant 
controls and dashed lines for subsequent PE patients. PE, preeclampsia; PP, postpartum.
200
150
100
50
2.5
2.0
1.5
1.0
0.5
0.0
Se
ru
m
 n
ep
hr
in
 le
ve
l (
ng
/m
L)
Ur
in
e 
ne
ph
rin
 le
ve
l (
ng
/m
L)
Gestational age (weeks) Gestational age (weeks)
11–15 11–1516–20 16–2021–28 21–2829–41 29–41PP PP
A B
405
Yun Ji Jung, et al.
https://doi.org/10.3349/ymj.2017.58.2.401
patients and clinicians suffer the fear of disease occurrence for 
substantial period of time. Thus, the use of urine nephrin that 
represents relatively shorter time interval between the rise and 
the onset of PE, compared with serum sFlt-1 and sEng, may 
clinically be more feasible in the prediction of subsequent de-
velopment of PE or in making decision at a timely basis. Fur-
thermore, urine nephrin may be incorporated together with 
other placenta-derived biomarkers in an effort to improve the 
predictability and/or accuracy of PE.23-30
Our study has several limitations. The main weakness of this 
study was a small study population in PE. Some of the analyses 
may not have enough power to demonstrate the statistical sig-
nificance. Second, there was a lack of information on some po-
tential confounders such as circadian variation of urine protein. 
Patients with glomerular proteinuria and fairly well-preserved 
renal function have circadian rhythm for proteinuria. Therefore, 
we were unable to adjust for this factors and to exclude a con-
founding effect on the result. The difference in the median ges-
tational age at sampling in the 3rd trimester between the con-
trol and the patient who subsequently developed PE may affect 
the result (36+1 and 33+1 wks, respectively, p=0.011). This may be 
the case, since serum nephrin tends to decrease with advance-
ment in gestation. However, the level of urine neprhin re-
mained consistent with narrow standard error, and the degree 
of increment was far greater than the control. Furthermore, 
when urine nephrin level of the PE group was compared to that 
of earlier gestational age control, the value was still significantly 
higher in PE group. Lastly, due to a small sample size of our 
study, feasibility of urine nephrin as a predictive factor in PE re-
mains to be assessed by prospective longitudinal study involv-
ing large number of pregnancies with subsequent PE.
In conclusion, as the onset of PE was preceded by the rise in 
the serum and urine nephrin in comparison to normal preg-
nancy, serum and urine nephrin may be useful as a predictive 
marker of PE.
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